Large institutional experience with dose-intensive chemotherapy and stem cell support in the management of sarcoma patients

• Verfasst von: Kasper, Bernd [VerfasserIn]
• Verfasst von: Dietrich, Sascha [VerfasserIn]
• Verfasst von: Mechtersheimer, Gunhild [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Verfasst von: Egerer, Gerlinde [VerfasserIn]
• Titel: Large institutional experience with dose-intensive chemotherapy and stem cell support in the management of sarcoma patients
• Verf.angabe: Bernd Kasper, Sascha Dietrich, Gunhild Mechtersheimer, Anthony D. Ho, Gerlinde Egerer
• Jahr: 2007
• Umfang: 7 S.
• Illustrationen: Diagramme
• Teil: volume:73
• Teil: year:2007
• Teil: number:1/2
• Teil: pages:58-64
• Teil: extent:7
• Fussnoten: Published online: March 11, 2008 ; Gesehen am 12.10.2021
• Titel Quelle: Enthalten in: Oncology
• Ort Quelle: Basel : Karger, 1967
• Jahr Quelle: 2007
• Band/Heft Quelle: 73(2007), 1/2, Seite 58-64
• ISSN Quelle: 1423-0232
• DOI: doi:10.1159/000120629
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1773407465

Abstract

Background: The prognosis of patients with advanced sarcoma remains poor. Whether high-dose chemotherapy with stem cell support improves the long-term outcome for these patients or not is controversial. Methods: We present a large institutional experience of sarcoma patients treated with this therapy option. Thirty-eight patients with bone (n = 17) and soft tissue sarcomas (n = 21) were included. Apart from haematological complications, no WHO grade III-IV complications were observed. One patient died due to cardiac arrest after transplantation. Results: Following chemotherapy and/or surgery, but prior to high-dose chemotherapy, diagnoses were made of: no evidence of disease (NED; n = 12), partial remission (n = 17), stable disease (n = 3) and progressive disease (PD; n = 6). Six patients died within 8 months due to PD, in 18 patients disease recurred and led to death and 13 patients are alive with/without disease. Median progression-free survival was 19.1 months (range: 0-121) for all patients, and 48.8 months (range: 3-121) for 12 patients with NED. Conclusion: A subgroup of patients with NED before high-dose chemotherapy gained survival benefit. Therefore, we emphasize the value of high-dose chemotherapy as a treatment option for younger patients with a good performance status in partial or complete remission.